Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Total Non-Current Liabilities (2022 - 2025)

Serina Therapeutics (SER) has disclosed Total Non-Current Liabilities for 4 consecutive years, with $3.7 million as the latest value for Q2 2025.

  • Quarterly Total Non-Current Liabilities fell 72.63% to $3.7 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $3.7 million through Jun 2025, down 72.63% year-over-year, with the annual reading at $2.6 million for FY2024, 45.78% down from the prior year.
  • Total Non-Current Liabilities hit $3.7 million in Q2 2025 for Serina Therapeutics, up from $2.6 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $32.2 million in Q1 2023 to a low of -$8.9 million in Q1 2024.
  • Historically, Total Non-Current Liabilities has averaged $10.8 million across 4 years, with a median of $13.2 million in 2022.
  • Biggest five-year swings in Total Non-Current Liabilities: skyrocketed 153.62% in 2023 and later plummeted 127.69% in 2024.
  • Year by year, Total Non-Current Liabilities stood at $20.4 million in 2022, then crashed by 76.16% to $4.9 million in 2023, then tumbled by 45.78% to $2.6 million in 2024, then soared by 42.22% to $3.7 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for SER at $3.7 million in Q2 2025, $2.6 million in Q1 2025, and $2.6 million in Q4 2024.